Bayesian Model Averaging Continuous Reassessment Method (BMA-CRM)
V1.0.0; Last Updated: 06/29/2017
Developed by Rongji Mu
^{1}
and Ying Yuan
^{2}
^{1}
School of Statistics, East China Normal University, Shanghai 200241, China
^{2}
Department of Biostatistics, MD Anderson Cancer Center, Houston, TX 77030
Simulation
Trial Conduct
Reference
Trial Setting
Target toxicity rate
Number of doses
Starting dose level
Starting dose level must be less than or equal to the total number of doses.
Starting dose level must be greater than 0.
Cohort size
Number of cohort
Choose a method
CRM
BMA-CRM
Enter skeleton delimited by comma
Enter Skeletons
Number of skeletons
Bayesian model averaging (BMA)
Bayesian model selection (BMS)
Enter Simulation Scenarios
Number of scenarios to be simulated
Number of trials to be simulated
Warning:You already reached the maximum number of trials you can Input!
Run Simulation
Operating Characteristics
×
Example
×
Example
×
Example
Trial Setting
Target toxicity rate
Current dose level
Using the same trial setting as in Simulation.
Current dose level must be less than or equal to the total number of doses.
Choose a Method
CRM
BMA-CRM
Total number of doses
Current dose level must be less than or equal to the total number of doses.
Current dose level must be less than or equal to the total number of doses.
Enter skeleton delimited by comma
Total number of doses
Number of skeletons
Current dose level must be less than or equal to the total number of doses.
Enter skeleton delimited by comma
Bayesian model averaging (BMA)
Bayesian model selection (BMS)
Error:You already reached the maximum number of doses you can Input!
Enter Trial Data
Dose Level
# of Pts treated
# of DLT
Run Trial
Dose Assignment
Data Summary
×
Example
×
Example
1. Yin, G. and Yuan, Y. (2009) Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. Journal of the American Statistical Association 104, 954-968.
2. Pan, H. and Yuan, Y. (2016) A Default Method to Specify Skeletons for Bayesian Model Averaging Continual Reassessment Method for Phase I Clinical Trials. Statistics in Medicine, 36, 266-279.